Advanced

Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients

Clyne, N. LU and Jogestrand, T. (1992) In Nephron 60(4). p.390-396
Abstract

Anemia is already present in patients with moderate renal failure and is a major cause of the decline in exercise capacity seen in these patients. We examined the effects of erythropoietin (EPO) treatment in 12 predialytic uremic patients (EPO group: mean age 46 ± 12 years; 6 men, 6 women) with a mean glomerular filtration rate (GFR) of 10 ± 4 ml/min x 1.73 m2. These patients were compared to a control group of 8 patients (5 men, 3 women). The observation period was 3 months. The EPO group received 300 U/kg body weight i.v. once a week. The EPO group increased their total hemoglobin (THb) from 323 ± 89 to 466 ± 128 g (p <0.001) and their hemoglobin concentration from 86 ± 8 to 117 ± 11 g/l (p <0.001). Their exercise... (More)

Anemia is already present in patients with moderate renal failure and is a major cause of the decline in exercise capacity seen in these patients. We examined the effects of erythropoietin (EPO) treatment in 12 predialytic uremic patients (EPO group: mean age 46 ± 12 years; 6 men, 6 women) with a mean glomerular filtration rate (GFR) of 10 ± 4 ml/min x 1.73 m2. These patients were compared to a control group of 8 patients (5 men, 3 women). The observation period was 3 months. The EPO group received 300 U/kg body weight i.v. once a week. The EPO group increased their total hemoglobin (THb) from 323 ± 89 to 466 ± 128 g (p <0.001) and their hemoglobin concentration from 86 ± 8 to 117 ± 11 g/l (p <0.001). Their exercise capacity, measured by a standardized exercise test on a bicycle ergometer, increased from 128 ± 45 to 147 ± 57 W (p <0.01). The control group did not change their THb (349 ± 124 and 357 ± 131 g), hemoglobin (93 ± 8 and 94 ± 10 g/l) or exercise capacity (98 ± 49 and 101 ± 50 W) during the observation period. There was a significant correlation between the increase in THb and the increase in exercise capacity in the EPO group (r = 0.81, p <0.005). The GFR was unchanged in both groups (EPO group :10 ± 4 and 10 ± 6 ml/min x 1.73 m2: control group: 8 ± 3 and 8 ± 3 ml/min x 1.73 m2). The median renal plasma flow did not change significantly in either group (EPO group: 42 and 27 ml/ min x 1.73 m2; control group: 34 and 28 ml/min x 1.73 m2). The median filtration fraction, however, increased signifcantly in the EPO group (0.21 to 0.30; p <0.05), while the filtration fraction in the control group was unchanged (0.22 and 0.25; NS). We conclude that erythropoietin treatment increases the THb in predialytic uremic patients, resulting in an improved exercise capacity without affecting GFR.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
keywords
Erythropoietin, Exercise capacity, Renal function, Uremia
in
Nephron
volume
60
issue
4
pages
7 pages
publisher
Karger
external identifiers
  • Scopus:0026523401
ISSN
0028-2766
language
English
LU publication?
no
id
b267c61a-ade5-43ff-b393-762e1699f21a
date added to LUP
2016-08-30 22:05:18
date last changed
2016-10-30 04:49:34
@misc{b267c61a-ade5-43ff-b393-762e1699f21a,
  abstract     = {<p>Anemia is already present in patients with moderate renal failure and is a major cause of the decline in exercise capacity seen in these patients. We examined the effects of erythropoietin (EPO) treatment in 12 predialytic uremic patients (EPO group: mean age 46 ± 12 years; 6 men, 6 women) with a mean glomerular filtration rate (GFR) of 10 ± 4 ml/min x 1.73 m<sup>2</sup>. These patients were compared to a control group of 8 patients (5 men, 3 women). The observation period was 3 months. The EPO group received 300 U/kg body weight i.v. once a week. The EPO group increased their total hemoglobin (THb) from 323 ± 89 to 466 ± 128 g (p &lt;0.001) and their hemoglobin concentration from 86 ± 8 to 117 ± 11 g/l (p &lt;0.001). Their exercise capacity, measured by a standardized exercise test on a bicycle ergometer, increased from 128 ± 45 to 147 ± 57 W (p &lt;0.01). The control group did not change their THb (349 ± 124 and 357 ± 131 g), hemoglobin (93 ± 8 and 94 ± 10 g/l) or exercise capacity (98 ± 49 and 101 ± 50 W) during the observation period. There was a significant correlation between the increase in THb and the increase in exercise capacity in the EPO group (r = 0.81, p &lt;0.005). The GFR was unchanged in both groups (EPO group :10 ± 4 and 10 ± 6 ml/min x 1.73 m<sup>2</sup>: control group: 8 ± 3 and 8 ± 3 ml/min x 1.73 m<sup>2</sup>). The median renal plasma flow did not change significantly in either group (EPO group: 42 and 27 ml/ min x 1.73 m<sup>2</sup>; control group: 34 and 28 ml/min x 1.73 m<sup>2</sup>). The median filtration fraction, however, increased signifcantly in the EPO group (0.21 to 0.30; p &lt;0.05), while the filtration fraction in the control group was unchanged (0.22 and 0.25; NS). We conclude that erythropoietin treatment increases the THb in predialytic uremic patients, resulting in an improved exercise capacity without affecting GFR.</p>},
  author       = {Clyne, N. and Jogestrand, T.},
  issn         = {0028-2766},
  keyword      = {Erythropoietin,Exercise capacity,Renal function,Uremia},
  language     = {eng},
  number       = {4},
  pages        = {390--396},
  publisher    = {ARRAY(0xad5c528)},
  series       = {Nephron},
  title        = {Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients},
  volume       = {60},
  year         = {1992},
}